Hoffenberg Edward J, Newman Heike, Collins Colm, Tarbell Sally, Leinwand Kristina
*Department of Pediatrics, Digestive Health Institute †Department of Regulatory Compliance ‡Department of Pediatrics, Mucosal Inflammation Program §Department of Psychiatry, University of Colorado School of Medicine, Aurora, CO.
J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):265-271. doi: 10.1097/MPG.0000000000001393.
The trend toward decriminalization of cannabis (marijuana) continues sweeping across the United States. Colorado has been a leader of legalization of medical and recreational cannabis use. The growing public interest in the medicinal properties of cannabis and its use by patients with a variety of illnesses including inflammatory bowel disease (IBD) makes it important for pediatric gastroenterologists to understand this movement and its potential effect on patients. This article describes the path to legalization and "medicalization" of cannabis in Colorado and the public perception of safety despite the known adverse health effects of use. We delineate the mammalian endocannabinoid system and our experience of caring for children and adolescents with IBD in an environment of increasing awareness and acceptance of its use. We then summarize the rationale for considering that cannabis may have beneficial and harmful effects for patients with IBD. Finally, we highlight the challenges federal laws impose on conducting research on cannabis in IBD. The intent of this article is to inform health care providers about the issues around cannabis use and research in adolescents and young adults with IBD.
大麻( marijuana )非刑事化的趋势继续席卷美国。科罗拉多州一直是医用和娱乐用大麻合法化的引领者。公众对大麻药用特性的兴趣日益浓厚,且患有包括炎症性肠病( IBD )在内的各种疾病的患者也在使用大麻,这使得儿科胃肠病学家了解这一动态及其对患者的潜在影响变得至关重要。本文描述了科罗拉多大麻合法化和 “ 药用化 ” 的历程,以及尽管已知使用大麻对健康有不良影响,但公众对其安全性的认知。我们阐述了哺乳动物内源性大麻素系统,以及在对大麻的认识和接受度不断提高的环境中,我们照顾患有 IBD 的儿童和青少年的经验。然后,我们总结了认为大麻可能对 IBD 患者产生有益和有害影响的理由。最后,我们强调了联邦法律对开展 IBD 患者大麻研究施加的挑战。本文旨在让医疗保健提供者了解 IBD 青少年和青年使用大麻及相关研究的相关问题。